The latest biotech news

News and Trends 29 May 2020

AI Drug Discovery Firm Exscientia Closes €54M Series C

UK-based Exscientia has closed a Series C financing round of €54M ($60M) to develop its artificial intelligence (AI) technology to guide drug discovery. The Danish investor Novo Holdings led the round with its first investment in the company. Additional funding also came from existing investors including drug development company Evotec and Chinese VC firm GT […]

May 29, 2020 - 3 minutesmins - By David Kirk

News and Trends 29 May 2020

Argenx Follows up Phase III Success with Giant €785M Global Offering

The Dutch biotech argenx has cashed in on recent positive phase III results by launching an enormous €784.7M ($862.5M) global share offering. Argenx’s fundraise swiftly follows the announcement of phase III trial results earlier this week, where its lead candidate antibody drug, efgartigimod, improved motor symptoms of patients with the chronic autoimmune disease myasthenia gravis. […]

May 29, 2020 - 2 minutesmins - By Jonathan Smith

central nervous system epilepsy parkinsons disease

News and Trends 29 May 2020

Spanish Neurology Biotech Launches with €7.6M Series A

Accure Therapeutics, a neurology biotech targeting central nervous system (CNS) conditions such as multiple sclerosis and Parkinson’s disease, has launched in Barcelona with a Series A of €7.6M. Alta Life Sciences, a life science venture capital firm based in the same city, and the Spanish governmental institution The Centre for Technological and Industrial Development funded […]

May 29, 2020 - 3 minutesmins - By Helen Albert

News and Trends 28 May 2020

French Startup Secures €2.3M to Advance Cancer RNA Immunotherapy

Lyon-based biopharmaceutical company Tollys has closed a Series A funding round of €2.3M to bring its lead RNA immunotherapy candidate to clinical trials in people with bladder cancer. The round was closed on the basis of the company reaching preclinical proof-of-concept for the drug. It brings the total amount raised by Tollys to €6.4M since […]

May 28, 2020 - 2 minutesmins - By Laura Cowen

News and Trends 28 May 2020

MSD Enters Covid-19 Vaccine Race by Acquiring Themis Bioscience

The US-based big pharma MSD has entered the race to be the first to develop an effective vaccine for Covid-19 by acquiring Austrian biotech Themis Bioscience and its vaccine technology for an undisclosed amount. MSD has been a bit slower than some of its contemporaries to announce its plans regarding a potential treatment or vaccine […]

May 28, 2020 - 3 minutesmins - By Helen Albert

gates foundation oxitec malaria mosquito

News and Trends 27 May 2020

‘Just Add Water’ GM Mosquitoes Suppress Wild Population by 95%

Water-soluble capsules containing the eggs of genetically modified mosquitoes developed by the UK company Oxitec have reduced the mosquito population in a dengue-infected urban environment in Brazil by 95% after 13 weeks. Aedes aegypti mosquitoes carry a number of infections including dengue, Zika, chikungunya, and yellow fever. Dengue has increased almost 15-fold over the last […]

May 27, 2020 - 4 minutesmins - By Helen Albert

News and Trends 26 May 2020

Argenx’s Rare Disease Treatment Strikes Gold in Phase III

The Dutch biotech argenx aims to apply for FDA approval of its lead candidate efgartigimod after the first-in-class drug improved motor symptoms of the autoimmune disease myasthenia gravis in a phase III trial. The phase III trial tested the effect of efgartigimod in 167 patients with generalized myasthenia gravis. In this incurable chronic condition, the […]

May 26, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 25 May 2020

Evonik and Beiersdorf Team Up to Turn CO₂ into Skin Care Products

The German companies Evonik and Beiersdorf will work together on a joint research project to investigate how bacteria can be used to turn carbon dioxide (CO₂) and water into raw materials for skincare products. The process will be built on Evonik’s artificial photosynthesis technology – being developed independently of this project in collaboration with Siemens […]

May 25, 2020 - 2 minutesmins - By Laura Cowen

balmes transplantation kidney disorders 1

News and Trends 22 May 2020

Phase II Fail Ends Swiss-US Drug for Rare Kidney Disease

An initially promising drug has failed to show benefits in a phase II trial for the rare kidney disease focal segmental glomerulosclerosis (FSGS), prompting the US biotech ChemoCentryx and its Swiss collaborator Vifor Pharma to drop it for this indication. Topline results from the phase II trial showed that 12 weeks of treatment with the […]

May 22, 2020 - 2 minutesmins - By Anita Chakraverty

News and Trends 20 May 2020

Phase II Success for Once-a-Day Eye Drops after Cataract Surgery

A nanoparticle steroid therapy developed by Swiss biotech Oculis has reduced eye pain and inflammation in a phase II trial in cataract surgery patients. This is the second positive phase II this year for the company, which closed a €31M Series B fundraising round at the beginning of 2019. In February this year, Oculis also […]

May 20, 2020 - 3 minutesmins - By Helen Albert

News and Trends 20 May 2020

Antibacterial Eliminates Recurrence of C. Difficile Infections in Phase II

MGB Biopharma has reported positive results from a phase II trial showing that its antibacterial treatment for Clostridium difficile infections cured 100% of the patients, who showed no recurrence four weeks after. The bacterium Clostridium difficile causes life-threatening infections in the intestine and is the most common cause of diarrhea. Current treatments against it […]

May 20, 2020 - 3 minutesmins - By Clara Rodríguez Fernández

novartis spinal muscular atrophy gene therapy

News and Trends 19 May 2020

Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU

Update (19/05/2020): The gene therapy Zolgensma, developed by the big pharma Novartis and approved in the US last year, has received conditional approval in Europe for the treatment of spinal muscular atrophy (SMA). The gene therapy is approved to treat patients with a clinical diagnosis of SMA type 1 or SMA patients that have up […]

May 19, 2020 - 5 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

AI Drug Discovery Firm Exscientia Closes €54M Series C

Argenx Follows up Phase III Success with Giant €785M Global Offering

Spanish Neurology Biotech Launches with €7.6M Series A

French Startup Secures €2.3M to Advance Cancer RNA Immunotherapy

MSD Enters Covid-19 Vaccine Race by Acquiring Themis Bioscience

‘Just Add Water’ GM Mosquitoes Suppress Wild Population by 95%

Argenx’s Rare Disease Treatment Strikes Gold in Phase III

Evonik and Beiersdorf Team Up to Turn CO₂ into Skin Care Products

Phase II Fail Ends Swiss-US Drug for Rare Kidney Disease

Phase II Success for Once-a-Day Eye Drops after Cataract Surgery

Antibacterial Eliminates Recurrence of C. Difficile Infections in Phase II

Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!